Protein-protein interactions as antibiotic targets: A medicinal chemistry perspective

Peter J Cossar; Peter J Lewis; Adam McCluskey

doi:10.1002/med.21519

Protein-protein interactions as antibiotic targets: A medicinal chemistry perspective

Med Res Rev. 2020 Mar;40(2):469-494. doi: 10.1002/med.21519. Epub 2018 Jul 13.

Authors

Peter J Cossar¹, Peter J Lewis², Adam McCluskey¹

Affiliations

¹ Discipline of Chemistry, School of Environmental & Life Sciences, The University of Newcastle, Callaghan, Australia.
² Centre for Chemical Biology and Clinical Pharmacology, Department of Biology, School of Environmental & Life Sciences, The University of Newcastle, Callaghan.

PMID: 30004586
DOI: 10.1002/med.21519

Abstract

There are 27 small molecule protein-protein interaction (PPI) modulators in Phase I, II, and III clinical trials targeting cancer, viruses, autoimmune disorders, and as immune suppression agents. Targeting PPIs as an antibiotic drug discovery strategy remains in relative infancy by comparison. However, a number of molecules are in development which target PPI within the replisome, divisome, transcriptome, and translatome are showing significant promise at the medicinal chemistry stage of drug development. Hence, the success of future PPI agents as antibiotics will build upon the techniques and design strategies of these molecules.

Keywords: antibacterial; antibiotic; protein-protein interaction (PPI).

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Anti-Bacterial Agents / pharmacology*
Chemistry, Pharmaceutical*
Clinical Trials as Topic
Drug Discovery
Humans
Protein Interaction Mapping*
Small Molecule Libraries / chemistry
Small Molecule Libraries / pharmacology

Substances

Anti-Bacterial Agents
Small Molecule Libraries